Valerio Therapeutics Société anonyme (C4X.F)
- Business Wire
Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates
PARIS, April 30, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today reported its consolidated results for the fiscal year ending December 31, 2023.
- Business Wire
Valerio Therapeutics Announces a Capital Reduction Motivated by Losses by Reducing the Nominal Value of the Company's Shares
PARIS, February 06, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces a reduction of the par value of its shares.
- Business Wire
Half-Year Liquidity Contract Statement for Valerio Therapeutics
PARIS, January 31, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)
